November 10, 2026 · American journal of ophthalmology · DOI: 10.1016/j.ajo.2026.11.002

High-Dose Intravitreal Topotecan for Refractory or Recurrent Retinoblastoma: Efficacy, Safety and Intraocular Cytokine Profiles.

Listen to this summary

This case series evaluated whether high-dose intravitreal topotecan (100 μg, given every four weeks) could salvage eyes with refractory or recurrent intraocular retinoblastoma. In 15 patients, the treatment achieved a 93% globe salvage rate, complete control of intraocular seeds, and complete regression of intraretinal tumors in 3 of 4 eyes, with no significant decline in electroretinography amplitude and no changes in 27 aqueous humor cytokines. The authors conclude that high-dose intravitreal topotecan is effective and appears safe, though the small, uncontrolled design and short follow-up limit firm conclusions about its use as first-line therapy.

Xintong Lin, Zhuqing Zheng, Haifeng Chen, Jiang Qian, Qiang Liu, Ruiqi Ma, Kang Xue

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play